Session (CTI)

ISSUE: Vaccine evaluation is still largely shaped by drug-centric HTA frameworks focused on individual-level outcomes (e.g., cost per QALY). While appropriate for therapeutic interventions, these approaches do not fully capture the population-level, time-sensitive, and transmission-related value of vaccines. Although challenges in targeting appropriate populations and demonstrating value are shared across health technologies, vaccines differ in their need for rapid, broad uptake to generate public health impact and interrupt transmission. As highlighted by lessons from COVID-19, delayed implementation can significantly undermine health and economic outcomes, reinforcing the importance of timely access and system readiness. In practice, translating vaccine value into policy adoption remains complex and fragmented. Multiple stakeholders, including HTA bodies, NITAGs, Ministries of Health and Ministries of Finance, operate with differing objectives, evidence expectations, and timelines. Real-world evidence (RWE) and implementation experience are often underutilized early in decision-making, contributing to delays between availability, evaluation, and national immunization program (NIP) adoption. OVERVIEW: The session will use Rotavirus and Dengue prevention as anchoring examples to discuss toward an integrated framework among HTA evaluation, policy guidance (NITAG) and real-world implementation insights Each panelist will speak about 10 minutes on reimbursement decision making for vaccine, delays and potential solutions from a different perspective. Finally, all panelists will come together for 15 minutes to reconcile their thoughts, reflect on challenges in applying the current HTA framework for drugs on vaccines, and brainstorm the roles of multiple stakeholders to sustainably address some of these challenges. The last 15 minutes will be allocated for questions and answers with the audience